Home Cart Sign in  
Chemical Structure| 1338540-63-8 Chemical Structure| 1338540-63-8

Structure of OTS514
CAS No.: 1338540-63-8

Chemical Structure| 1338540-63-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

OTS514 is a highly potent TOPK inhibitor with an IC50 value of 2.6 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of OTS514

CAS No. :1338540-63-8
Formula : C21H20N2O2S
M.W : 364.46
SMILES Code : O=C1NC2=C(C(C3=CC=C([C@@H](C)CN)C=C3)=C(O)C=C2C)C4=C1SC=C4
MDL No. :MFCD29924710
InChI Key :OETLNMOJNONWOY-LBPRGKRZSA-N
Pubchem ID :67448836

Safety of OTS514

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of OTS514

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SW48 20 nM 24 hours Inhibited cell proliferation and induced apoptosis Front Pharmacol. 2022 Jan 18;12:772926
LoVo 20 nM 48 hours Inhibited cell proliferation and induced apoptosis Front Pharmacol. 2022 Jan 18;12:772926
HCT116 20 nM 48 hours Inhibited cell proliferation and induced apoptosis Front Pharmacol. 2022 Jan 18;12:772926
HaCaT cells 5 nM, 10 nM, 20 nM 12 hours Inhibited TOPK activity and reduced the expression of neutrophil chemokines CXCL1, CXCL2, and CXCL8 Cell Commun Signal. 2024 Aug 1;22(1):386
CH22 cells 1, 2, 5, 10 nM 2, 3, 5 days To evaluate the effect of OTS514 on chordoma cell growth and proliferation. Results showed that OTS514 decreased cell viability in a dose- and time-dependent manner in UCH2 and CH22 cells, with IC50 values of 1.36-46.29 and 0.50-2.79 nmol/L, respectively. Cell Prolif. 2020 Oct;53(10):e12901
UCH2 cells 1, 2, 5, 10 nM 2, 3, 5 days To evaluate the effect of OTS514 on chordoma cell growth and proliferation. Results showed that OTS514 decreased cell viability in a dose- and time-dependent manner in UCH2 and CH22 cells, with IC50 values of 1.36-46.29 and 0.50-2.79 nmol/L, respectively. Cell Prolif. 2020 Oct;53(10):e12901
U2OS 6.25, 12.5, 25, 50 nM 2, 3, or 5 days To evaluate the inhibitory effect of OTS514 on osteosarcoma cell proliferation. Results showed that OTS514 significantly reduced the viability of KHOS and U2OS cells in a dose- and time-dependent manner, with IC50 values of 4.77–21.17 nM and 6.34–42.10 nM after 5 days of treatment, respectively. Mol Oncol. 2021 Dec;15(12):3721-3737
KHOS 6.25, 12.5, 25, 50 nM 2, 3, or 5 days To evaluate the inhibitory effect of OTS514 on osteosarcoma cell proliferation. Results showed that OTS514 significantly reduced the viability of KHOS and U2OS cells in a dose- and time-dependent manner, with IC50 values of 4.77–21.17 nM and 6.34–42.10 nM after 5 days of treatment, respectively. Mol Oncol. 2021 Dec;15(12):3721-3737
HAP1-TOPK k.o. cells 100 nM 30 minutes prior to TOPKi-NBD Validate the specificity of TOPKi-NBD in non-TOPK-expressing cells Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):1003-1010
H446 10 or 20 nM 48 hours Evaluate the growth-suppressive effect of OTS514 on SCLC cells, showing that OTS514 reduced TOPK protein levels in a dose-dependent manner Cancer Sci. 2017 Mar;108(3):488-496
H69AR 10 or 20 nM 48 hours Evaluate the growth-suppressive effect of OTS514 on SCLC cells, showing that OTS514 reduced TOPK protein levels in a dose-dependent manner Cancer Sci. 2017 Mar;108(3):488-496
DMS114 10 or 20 nM 48 hours Evaluate the growth-suppressive effect of OTS514 on SCLC cells, showing that OTS514 reduced TOPK protein levels in a dose-dependent manner Cancer Sci. 2017 Mar;108(3):488-496
SKOV3 20, 50, 100 nM 48 hours OTS514 significantly inhibited ovarian cancer cell proliferation and enhanced the lethal effect of cisplatin. Cell Death Dis. 2019 Feb 18;10(3):166
A2780 20, 50, 100 nM 48 hours OTS514 significantly inhibited ovarian cancer cell proliferation and enhanced the lethal effect of cisplatin. Cell Death Dis. 2019 Feb 18;10(3):166
H2171 42.6 nM (IC50) 72 hours Evaluate the growth-suppressive effect of OTS514 on suspension SCLC cells, showing weaker effects on cells with low TOPK expression Cancer Sci. 2017 Mar;108(3):488-496
H146 39.3 nM (IC50) 72 hours Evaluate the growth-suppressive effect of OTS514 on suspension SCLC cells, showing weaker effects on cells with low TOPK expression Cancer Sci. 2017 Mar;108(3):488-496
H524 2.6 nM (IC50) 72 hours Evaluate the growth-suppressive effect of OTS514 on suspension SCLC cells, showing stronger effects on cells with high TOPK expression Cancer Sci. 2017 Mar;108(3):488-496
H82 7.2 nM (IC50) 72 hours Evaluate the growth-suppressive effect of OTS514 on suspension SCLC cells, showing stronger effects on cells with high TOPK expression Cancer Sci. 2017 Mar;108(3):488-496
H69 0.4 nM (IC50) 72 hours Evaluate the growth-suppressive effect of OTS514 on suspension SCLC cells, showing stronger effects on cells with high TOPK expression Cancer Sci. 2017 Mar;108(3):488-496

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice IMQ-induced psoriasis-like dermatitis model Topical application 100mg (dorsal skin) and 20mg (ear skin) Once daily for 5 days Alleviated already-established psoriasis-like dermatitis symptoms, including erythema, scaling, and epidermal thickening Cell Commun Signal. 2024 Aug 1;22(1):386
Nude mice KRASG12C A549 xenograft model Intraperitoneal injection 2.5 mg/kg Twice a week for 4 weeks OTS514 enhanced the anticancer effect of 5-FU, and the combination with AMG510 showed synergistic anti-tumor effects J Cell Mol Med. 2023 Jun;27(12):1637-1652
BALB/c nude mice Ovarian cancer xenograft model Oral 25 mg/kg Once daily for 15 days OTS514 significantly enhanced the growth inhibitory effect of cisplatin on ovarian cancer xenograft models. Cell Death Dis. 2019 Feb 18;10(3):166
Nude mice HCT116 colorectal cancer xenograft model Intravenous injection 50 μg/mouse Single injection, analyzed after 5 hours Evaluate tumor-specific uptake of TOPKi-NBD in vivo Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):1003-1010

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.72mL

2.74mL

1.37mL

27.44mL

5.49mL

2.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories